Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
J.Molner ASOTSE:MOLNR -0.53%40 PS Ratio is 27.75 as of Aug. 31, 2026, which is 21% above its 10-year median of 22.97. GuruFocus rates OTSE:MOLNR with a GF Score™ of 40/100 and a GF Value™ of €19.62 (Fairly Valued). The stock has 7 warning signs investors should review. Among 952 Drug Manufacturers companies, J.Molner AS ranks worse than 95.27% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, J.Molner AS's share price is €18.90.
J.Molner AS's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.68. Hence, J.Molner AS's PS Ratio for today is 27.75.
The historical rank and industry rank for J.Molner AS's PS Ratio or its related term are showing as below:
OTSE:MOLNR'
s PS Ratio Range Over the Past 10 Years
Min: 15.63 Med: 22.97 Max: 114.58
Current: 27.75
During the past 5 years, J.Molner AS's highest PS Ratio was 114.58. The lowest was 15.63. And the median was 22.97.
OTSE:MOLNR's PS Ratio is ranked worse than 95.27% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.375
vs OTSE:MOLNR: 27.75
J.Molner AS revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of J.Molner AS was -49.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 79.60% per year.
During the past 5 years, J.Molner AS's highest 3-Year average Revenue per Share Growth Rate was 79.60% per year. The lowest was 62.80% per year. And the median was 71.20% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
J.Molner AS PS Ratio Related Terms
J.Molner AS PS Ratio Historical Data
* Premium members only.
The historical data trend for J.Molner AS's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OTSE:MOLNR vs ZTS, UTHR, VTRS: PS Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, J.Molner AS's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
J.Molner AS PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, J.Molner AS's PS Ratio distribution charts can be found below:
* The bar in red indicates where J.Molner AS's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
J.Molner AS's Share Price of today is €18.90.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. J.Molner AS's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.68.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
J.Molner AS (OTSE:MOLNR) has a PS Ratio of 27.75 as of Aug. 31, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on J.Molner AS and its competitors. This is 21% above median its historical median of 22.97. Over the past decade, J.Molner AS's PS Ratio has ranged from 15.63 to 114.58. According to the industry distribution chart, J.Molner AS ranks #907 out of 952 companies in the Drug Manufacturers industry, placing it in the top 95.3%.
Is J.Molner AS's PS Ratio too high?
J.Molner AS's current PS Ratio of 27.75 is 21% above median its 10-year median of 22.97. Over the past 10 years, this metric has ranged from a low of 15.63 to a high of 114.58. The Drug Manufacturers industry median PS Ratio is 2.38. J.Molner AS's value of 27.75 is 1068.4% above this industry median. Based on the distribution chart, J.Molner AS ranks #907 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, J.Molner AS has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does J.Molner AS's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, J.Molner AS ranks #907 out of 952 companies for PS Ratio. This places J.Molner AS in the lower half of its industry. The industry median PS Ratio is 2.38. J.Molner AS's value of 27.75 is 1068.4% above this benchmark. Historically, J.Molner AS's own PS Ratio has ranged from 15.63 to 114.58 over the past decade. While the company's 10-year median is 22.97 vs. the industry median of 2.38, J.Molner AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.38, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. J.Molner AS's current PS Ratio of 27.75 is 1068.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on J.Molner AS and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. J.Molner AS's current PS Ratio is 27.75, which is 21% above median its own 10-year median of 22.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J.Molner AS stock overvalued right now?
Based on GuruFocus' analysis, J.Molner AS (OTSE:MOLNR) is currently considered Fairly Valued. The stock's GF Value™ is €19.62, compared to a current price of €18.90 — trading 3.7% below its estimated fair value. The current PS Ratio is 27.75, which is 21% above median its 10-year median of 22.97 and 1068.4% above the Drug Manufacturers industry median of 2.38. J.Molner AS's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For J.Molner AS (OTSE:MOLNR), the current PS Ratio is 27.75 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is J.Molner AS (OTSE:MOLNR) Overvalued in 2026?
Based on GuruFocus' analysis, J.Molner AS stock appears to be undervalued.
The current stock price of €18.90 is trading 3.7% below its estimated GF Value™ of €19.62.
GuruFocus considers J.Molner AS to be Fairly Valued.
Key valuation signals for OTSE:MOLNR:
PS Ratio: 27.75 (21% above median its 10-year median of 22.97)
GF Value™: €19.62 vs. price of €18.90 (3.7% below fair value)
Industry Position: 1068.4% above the Drug Manufacturers median (#907 of 952)
No single metric tells the full story. See the OTSE:MOLNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
J.Molner AS is an Estonia-based company engaged in research and development in the field of biotechnology. It is developing a portfolio of generic drug products for the United States and Canadian markets, consisting of both in-house developed medicines and acquired and in-licensed products. It operates through two complementary business units: internal generic drug development and specialized pharmaceutical services. It develops and commercializes sterile injectable, ophthalmic, and dermatology generic drugs, while also providing drug development services, analytical chemistry and stability testing. Its activities are divided into two business segments, Generic Drugs and Services, with Services generating maximum revenue. The Company generates maximum revenue from the United States.
40GF Score
Get the complete analysis for OTSE:MOLNR
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTSE:MOLNR has been successfully added to your 
